Contract Manufacturing, General

Apr 02, 2007
BioPharm International
By BioPharm International Editors
Partnering with a surging number of CROs, CMOs, CSOs, and other niche providers, biopharm companies in 2007 will have an estimated spend of more than $7 billion on international clinical trial outsourcing alone.
Mar 01, 2007
BioPharm International
The three largest players have accumulated, or are in the process of accumulating, nearly a million liters of capacity between them.
Feb 01, 2007
BioPharm International
By BioPharm International Editors
The changes in biologics manufacturing regulations contained in the 1997 FDA Modernization Act significantly bolstered the growth of CMOs.
Nov 01, 2006
BioPharm International
By BioPharm International Editors
In the rush to save money, the consequences of potential problems often are ignored.
Oct 01, 2006
BioPharm International
A major shift is occurring in the way the biopharmaceutical industry sources goods and services. Price pressures at the retail end of the value chain and a difficult fundraising environment are forcing biopharmaceutical companies to take greater control of their costs. Purchased goods and services, including contract research and manufacturing services as well as raw materials and laboratory supplies, are a major expense in most companies, so control of those purchasing decisions is coming in for special scrutiny.
Jul 01, 2006
BioPharm International
The lack of biomanufacturer acquisitions seems surprising.
Apr 01, 2006
BioPharm International
Interestingly, it is companies that already have the most capacity available to them that are building even more.
Feb 01, 2006
BioPharm International
Before designing cleaning procedures, it's vital to know all physical and chemical characteristics of the product ingredients.
Feb 01, 2006
BioPharm International
Moving aggressively to implement its Vision 2010 strategy, which debuted in October 2005, DSM N.V. (Heerlen, Netherlands) announced in December 2005 that it would shut down its Montreal biomanufacturing facility in early 2006. The move doesn't signal an exit from manufacturing, however, but a change in focus; DSM will simultaneously expand its expression-technology relationship with Crucell (Leiden, the Netherlands). Both moves reflect changing circumstances in the biomanufacturing sector.
native1_300x100
lorem ipsum